Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
复制标题
DOI：
10.1038/s41586-021-03681-2
复制
发表时间：
2021-08
期刊：
影响因子：
64.8
通讯作者：
Barouch DH
中科院分区：
文献类型：
--
作者：
Alter G;Yu J;Liu J;Chandrashekar A;Borducchi EN;Tostanoski LH;McMahan K;Jacob-Dolan C;Martinez DR;Chang A;Anioke T;Lifton M;Nkolola J;Stephenson KE;Atyeo C;Shin S;Fields P;Kaplan I;Robins H;Amanat F;Krammer F;Baric RS;Le Gars M;Sadoff J;de Groot AM;Heerwegh D;Struyf F;Douoguih M;van Hoof J;Schuitemaker H;Barouch DH
Ad26.COV2.S 疫苗已证明对有症状的 COVID-19 具有临床疗效，包括对对中和抗体部分耐药的 B.1.351 变体。然而，这种疫苗在人体中针对令人关注的 SARS-CoV-2 变体的免疫原性仍不清楚。在这里，我们报告了来自 COV1001 I-IIa 期临床试验的 20 名 Ad26.COV2.S 疫苗接种者针对原始 SARS-CoV-2 毒株 WA1/2020 以及针对相关 B.1.1.7、CAL.20C、P.1 和 B.1.351 变种的体液和细胞免疫反应。与疫苗接种后第 71 天的 WA1/2020 相比，Ad26.COV2.S 诱导的针对 B.1.351 和 P.1 变体的中值假病毒中和抗体滴度分别降低了 5.0 倍和 3.3 倍。与 WA1/2020 相比，针对 B.1.351 和 P.1 变体的中位结合抗体滴度分别降低了 2.9 倍和 2.7 倍。针对 B.1.351 变体，抗体依赖性细胞吞噬作用、补体沉积和自然杀伤细胞激活反应在很大程度上得以保留。 CD8 和 CD4 T 细胞反应，包括中枢和效应记忆反应，在 WA1/2020、B.1.1.7、B.1.351、P.1 和 CAL.20C 变体之间具有可比性。这些数据表明，针对 B.1.351 和 P.1 变体，Ad26.COV2.S 诱导的中和抗体反应减少，但针对 SARS-CoV-2 变体，功能性非中和抗体反应和 T 细胞反应在很大程度上得以保留。这些发现对于针对 SARS-CoV-2 相关变种的疫苗保护具有重要意义。 Ad26.COV2.S 疫苗针对 B1.351 和 P.1 SARS-CoV-2 变体的免疫原性分析显示，中和抗体滴度降低，但 T 细胞反应和抗体依赖性效应器功能相当。
The Ad26.COV2.S vaccine has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I–IIa clinical trial against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern. Analysis of the immunogenicity of the Ad26.COV2.S vaccine against the B1.351 and P.1 SARS-CoV-2 variants of concern shows reduced neutralization antibody titres, but comparable T cell responses and antibody-dependent effector functions.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
120.7
作者：
Stephenson, Kathryn E.;Le Gars, Mathieu;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
影响因子：
64.5
作者：
Chung AW;Kumar MP;Arnold KB;Yu WH;Schoen MK;Dunphy LJ;Suscovich TJ;Frahm N;Linde C;Mahan AE;Hoffner M;Streeck H;Ackerman ME;McElrath MJ;Schuitemaker H;Pau MG;Baden LR;Kim JH;Michael NL;Barouch DH;Lauffenburger DA;Alter G
通讯作者：
Alter G
影响因子：
56.9
作者：
Yu, Jingyou;Tostanoski, Lisa H.;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
影响因子：
56.9
作者：
Chandrashekar, Abishek;Liu, Jinyan;Barouch, Dan H.
通讯作者：
Barouch, Dan H.